Market anticipates Jiangxi Fushine Pharmaceutical's revenue to underperform industry figures, leading to a lower P/S. Investors foresee limited growth rates persisting, reducing their willingness to pay for the stock. If recent revenue trends persist, a share price reversal seems unlikely.